1. Epigenomic biomarkers insights in PBMCs for prognostic assessment of ECMO-treated cardiogenic shock patients
- Author
-
Yi-Jing Hsiao, Su-Chien Chiang, Chih-Hsien Wang, Nai-Hsin Chi, Hsi-Yu Yu, Tsai-Hsia Hong, Hsuan-Yu Chen, Chien-Yu Lin, Shuenn-Wen Kuo, Kang-Yi Su, Wen-Je Ko, Li-Ming Hsu, Chih-An Lin, Chiou-Ling Cheng, Yan-Ming Chen, Yih-Sharng Chen, and Sung-Liang Yu
- Subjects
ECMO ,Prognostic biomarker ,Epigenome ,Medicine ,Genetics ,QH426-470 - Abstract
Abstract Objective As the global use of extracorporeal membrane oxygenation (ECMO) treatment increases, survival rates have not correspondingly improved, emphasizing the need for refined patient selection to optimize resource allocation. Currently, prognostic markers at the molecular level are limited. Methods Thirty-four cardiogenic shock (CS) patients were prospectively enrolled, and peripheral blood mononuclear cells (PBMCs) were collected at the initiation of ECMO (t0), two-hour post-installation (t2), and upon removal of ECMO (tr). The PBMCs were analyzed by comprehensive epigenomic assays. Using the Wilcoxon signed-rank test and least absolute shrinkage and selection operator (LASSO) regression, 485,577 DNA methylation features were analyzed and selected from the t0 and tr datasets. A random forest classifier was developed using the t0 dataset and evaluated on the t2 dataset. Two models based on DNA methylation features were constructed and assessed using receiver operating characteristic (ROC) curves and Kaplan–Meier survival analyses. Results The ten-feature and four-feature models for predicting in-hospital mortality attained area under the curve (AUC) values of 0.78 and 0.72, respectively, with LASSO alpha values of 0.2 and 0.25. In contrast, clinical evaluation systems, including ICU scoring systems and the survival after venoarterial ECMO (SAVE) score, did not achieve statistical significance. Moreover, our models showed significant associations with in-hospital survival (p
- Published
- 2024
- Full Text
- View/download PDF